NCT01813539View on ClinicalTrials.gov

A Study of ARGX-110 in Participants With Advanced Malignancies

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

99

Participants

Timeline

Start Date

February 27, 2013

Primary Completion Date

July 10, 2020

Study Completion Date

July 10, 2020

Conditions

Neoplasms

Interventions

DRUG

ARGX-110

ARGX-110 will be administered as an IV infusion.

Trial Locations (8)

Unknown

Brussels

Edegem

Ghent

Bordeaux

Lille

Paris

Pierre-Bénite

Villejuif

Sponsors

Lead Sponsor

OncoVerity, Inc.

Collaborators (1)

All Listed Sponsors

collaborator

argenx

INDUSTRY

collaborator

Janssen Research & Development, LLC

INDUSTRY

lead

OncoVerity, Inc.

INDUSTRY